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Neurobiology of Disease
Reduced Efficacy of Anti-A Immunotherapy in a Mouse
Model of Amyloid Deposition and Vascular Cognitive
Impairment Comorbidity
Erica M. Weekman,1,2 Tiffany L. Sudduth,1,2 Carly N. Caverly,1,2 Timothy J. Kopper,2 XOliver W. Phillips,1,2
Dave K. Powell,3,4 and Donna M. Wilcock1,2
1Sanders-Brown Center on Aging, 2Department of Physiology, 3Magnetic Resonance Imaging and Spectroscopy Center, 4Department of Biomedical
Engineering, University of Kentucky, Lexington, Kentucky 40536
Vascular cognitive impairment and dementia (VCID) is the second most common form of dementia behind Alzheimer’s disease (AD). It
is estimated that 40% of AD patients also have some form of VCID. One promising therapeutic for AD is anti-A immunotherapy, which
uses antibodies against A to clear it from the brain. While successful in clearing A and improving cognition in mice, anti-A immu-
notherapy failed to reach primary cognitive outcomes in several different clinical trials. We hypothesized that one potential reason the
anti-A immunotherapy clinical trials were unsuccessful was due to this high percentage of VCID comorbidity in the AD population. We
used our unique model of VCID-amyloid comorbidity to test this hypothesis. We placed 9-month-old wild-type and APP/PS1 mice on
either a control diet or a diet that induces hyperhomocysteinemia (HHcy). After being placed on the diet for 3 months, the mice then
received intraperotineal injections of either IgG2a control or 3D6 for another 3 months. While we found that treatment of our comorbidity
model with 3D6 resulted in decreased total A levels, there was no cognitive benefit of the anti-A immunotherapy in our AD/VCID mice.
Further, microhemorrhages were increased by 3D6 in the APP/PS1/control but further increased in an additive fashion when 3D6 was
administered to the APP/PS1/HHcy mice. This suggests that the use of anti-A immunotherapy in patients with both AD and VCID would
be ineffective on cognitive outcomes.
Key words: amyloid; immunotherapy; microglia; microhemorrhage; mixed dementia; vascular cognitive impairment
Introduction
Alzheimer’s disease (AD) is the most common form of dementia
and is characterized pathologically by amyloid plaques, com-
posed of aggregated amyloid  (A) peptide, and neurofibrillary
tangles, comprised of hyperphosphorylated tau (Braak and
Braak, 1995; Alzheimer’s Association, 2015). Vascular cognitive
impairment and dementia (VCID) is the second most common
form of dementia and results from disruptions in blood flow to
the brain, such as stroke, hypoperfusion of the brain, microhem-
orrhages, and vasogenic edema (Gorelick et al., 2011). VCID and
AD are not mutually exclusive though; it is estimated that 40% of
AD patients also have some form of VCID (Bowler et al., 1998;
Zekry et al., 2002; Langa et al., 2004; Van Iterson et al., 2015).
The most common hypothesis for the progression of AD is the
amyloid cascade hypothesis, which states that A aggregation
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Significance Statement
Despite significant mouse model data demonstrating both pathological and cognitive efficacy of anti-A immunotherapy for the
treatment of Alzheimer’s disease, clinical trial outcomes have been underwhelming, failing to meet any primary endpoints. We
show here that vascular cognitive impairment and dementia (VCID) comorbidity eliminates cognitive efficacy of anti-A immu-
notherapy, despite amyloid clearance. Further, cerebrovascular adverse events of the anti-A immunotherapy are significantly
exacerbated by the VCID comorbidity. These data suggest that VCID comorbidity with Alzheimer’s disease may mute the response
to anti-A immunotherapy.
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leads to hyperphosphorylation of tau and tangle formation,
which then leads to neurodegeneration (Hardy and Higgins,
1992; Hardy and Selkoe, 2002). As the leading hypothesis for the
progression of AD, amyloid deposition and brain A have be-
come popular targets for many AD therapeutics. Immunother-
apy targeting A has been one of the most promising therapeutic
interventions for AD since its initial report in 1999 (Schenk et al.,
1999). Anti-A immunotherapy uses antibodies targeting A to
reduce brain A burden. Proposed mechanisms of action include
microglial recruitment and Fc receptor-mediated phagocytosis
(Bard et al., 2000; Wilcock et al., 2003), catalytic disaggregation
and solublization (Solomon et al., 1997), and the peripheral sink
mechanism (DeMattos et al., 2001). The relative contribution of
each mechanism on the overall efficacy of the antibody likely
relies on the isotype and epitope of the specific antibody (Bard et
al., 2000; Bacskai et al., 2001; Wilcock et al., 2003; Wilcock and
Colton, 2009; Zago et al., 2012).
While preclinical mouse model studies have repeatedly demon-
strated significant efficacy of anti-A immunotherapy, both in re-
ducing amyloid burden and improving cognition (Schenk et al.,
1999; Morgan et al., 2000; Wilcock et al., 2004a, b), the clinical trials
have remained underwhelming, failing to meet primary endpoints
for efficacy in a number of trials to date (Salloway et al., 2014; Siem-
ers et al., 2016). While there has been discussion in the field that one
reason for the lack of efficacy in clinical trials is that the disease is too
advanced, we hypothesize that one reason for the lack of efficacy in
clinical trials is the comorbidity of other dementia-causing patholo-
gies, such as VCID, as well as AD pathology.
To test our hypothesis, we are using our recently developed
mouse model of amyloid deposition comorbid with VCID (APP/
PS1  HHcy) (Sudduth et al., 2014), which develops additive
cognitive deficits and redistribution of amyloid favoring the de-
position of cerebral amyloid angiopathy (CAA). Using our co-
morbidity model, we administered 3D6, an anti-A antibody, or
IgG2a, a control antibody to test passive immunotherapy efficacy
in a mixed dementia mouse model. We found that there was no
cognitive benefit of immunotherapy in our comorbidity
model despite comparable reductions in total amyloid bur-
den. This was accompanied by a reduced immune response to
the immunotherapy.
Materials and Methods
Animals. Female and male wild-type (WT) and APP/PS1 mice (C57BL/6
mice carrying human APPSwe and PS1-dE9 mutations) (Jankowsky et
al., 2004) were bred in house and aged 9 months. Thirty-five WT mice
and 33 APP/PS1 mice were placed on either a diet with low levels of folate,
vitamins B6 and B12 and enriched with methionine (HHcy study group)
or a control diet with normal levels of folate, vitamins B6 and B12 and
methionine (control study group). The HHcy diet was Harlan Teklad
TD97345, and the control diet was Harlan Teklad 5001 C (both from
Harlan Laboratories). Once mice had received the diet for 3 months, they
began weekly intraperitoneal injections of either 3D6 or IgG2a at 10
mg/kg (Eli Lilly) for 3 months. The anti-A antibody 3D6, which is an
IgG2b isotype, binds to both soluble and insoluble A at the extreme
amino terminus (A1–5) (Racke et al., 2005; Demattos et al., 2012). Al-
though the control antibody and the anti-A antibody are not similar
isotypes, they both have similar immune functions, with IgG2a actually
having a higher affinity for FcR1 (Gessner et al., 1998). Control IgG2a
antibodies have been shown to have no effect on amyloid burden (De-
mattos et al., 2012). This study was approved by the University of Ken-
tucky Institutional Animal Care and Use Committee and conformed to
the National Institutes of Health Guide for the care and use of animals in
research. Behavioral testing and MRI were also performed, and an exper-
imental timeline with the number of animals per group is shown in
Figure 1A, B.
Behavior testing. Radial arm water maze (RAWM) testing was per-
formed at the University of Kentucky Rodent Behavior Core. The 2 d
RAWM was performed as previously described (Alamed et al., 2006).
Briefly, a six arm maze was submerged in a pool of water with a goal
platform placed at the end of one arm. Each mouse was subjected to 15
trials each day, with the mouse starting in a different arm for each trial
and the goal platform remaining in the same arm. The number of errors
(the number of incorrect arm entries) was counted over a 60 s period.
Errors were averaged for 3 trials resulting in 10 blocks over the 2 d. Blocks
1–5 comprise day 1 trials, whereas blocks 6 –10 comprise day 2 trials.
MRI. A subset of study mice were imaged by T2* MRI. Three or four
mice from each group were imaged 3 months after starting diet but
before beginning intraperitoneal antibody injections, again halfway
through intraperitoneal antibody injections, and a third time immedi-
ately before tissue collection. Mice were imaged with a 7-T Bruker Clin-
Scan MRI system (Bruker) with an MRI CryoProbe, delivering 2.5 the
signal to noise of a standard room temperature radiofrequency coil, lo-
cated at the Magnetic Resonance Imaging and Spectroscopy Center at the
University of Kentucky. Fourteen coronal slices were acquired with a
FLASH sequence with a TR 165 ms, TE 15.3 ms, 25 degree flip angle,
448  448 matrix, 0.4 mm thick, 20% gap, 0.033 mm  0.033 mm
resolution, 10 averages, and TA 24 min. Mice were anesthetized with
1.3% isoflorane using an MRI compatible vaporizer. They were then
positioned prone and held in place on the scanning bed using tooth and
ear bars. The animals were maintained at 37° with a water heated scan-
ning bed. Body temperature, heart, and respiration rates were moni-
tored. T2* MRI images were analyzed by one blinded investigator who
identified abnormalities that resembled hemorrhagic infarcts. These in-
farcts were counted, and this number was normalized to the number of
images counted to provide a per section count.
Tissue processing and histology. After a lethal injection of Beuthanasia-D,
blood was collected for plasma and mice were perfused intracardially with 25
ml normal saline. Brains were removed rapidly and bisected in the midsag-
gital plane with the left side being immersion fixed in 4% PFA for 24 h. The
right side was dissected with the frontal cortex and hippocampus flash frozen
in liquid nitrogen and then stored at 80°C. The left hemibrain was passed
through a series of 10%, 20%, and 30% sucrose solutions for cryoprotection
before sectioning. Using a sliding microtome, 25 m frozen horizontal sec-
tions were collected and stored free floating in 1 DPBS-containing sodium
azide at 4°C.
Eight sections spaced 600 m apart were selected for free floating
immunohistochemistry for CD11b (rat monoclonal, AbD Serotec,
1:1000 dilution) and total A (rabbit polyclonal, Invitrogen, 1:3000 di-
Table 1. Genes for real-time PCR
Gene of interest PMID TaqMan ID
IL1 NM_008361.3 Mm0.222830
TNF NM_013693.3 Mm0.1293
IL12a NM_008351.2 Mm0.103783
IL12b NM_008352.2 Mm0.239707
Marco NM_010766.2 Mm0.1856
IL10 NM_010548.2 Mm0.874
ARG1 NM_007482.3 Mm0.154144
YM1 NM_009892.2 Mm0.387173
Fizz NM_020509.3 Mm0.441868
IL1Ra NM_031167.5 Mm0.882
CD86 NM_019388.3 Mm0.1452
FcR1 NM_010186.5 Mm0.150
FcR3 NM_010188.5 Mm0.22119
TGF1 NM_011577.1 Mm0.248380
MRC1 NM_008625.2 Mm0.2019
MMP14 NM_008608.3 Mm0.280175
MMP2 NM_008610.2 Mm0.29564
TIMP2 NM_011594.3 Mm0.206505
MMP3 NM_010809.1 Mm0.4993
MMP9 NM_013599.3 Mm0.4406
TIMP1 NM_001044384.1 Mm0.8245
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lution). Immunohistochemistry was per-
formed as previously described (Wilcock et al.,
2008). Stained sections were mounted, air
dried overnight, dehydrated, and coverslipped
in DPX (Electron Microscopy Sciences). Anal-
ysis was performed by measuring the percent
area occupied by positive immunostain using
the Nikon Elements AR image analysis system
as described previously (Sudduth et al., 2012).
Eight sections spaced 600 m apart were
mounted on slides and stained for Congo red
and Prussian blue as previously described
(Wilcock et al., 2004b, 2006). Neutral red was
used as a counterstain for Prussian blue. Congo
red analysis was performed using the Zeiss
Axio Scan.Z1 Slide Scanner (Carl Zeiss Micros-
copy) and the Nikon Elements AR image anal-
ysis system.
Plasma was analyzed for total homocysteine
by the Clinical Laboratory of the University of
Kentucky Hospital Laboratories.
A ELISA. Biochemical analysis of A levels
was performed as previously described (Week-
man et al., 2014). Briefly, soluble protein was
extracted from the right frontal cortex using
PBS with complete protease and phosphatase
inhibitor (Pierce Biotechnology). After centrif-
ugation, the supernatant was labeled the “sol-
uble” extract, and the pellet was homogenized
in 70% formic acid. After centrifugation and
neutralization with 1 M Tris-HCl, the superna-
tant was labeled the “insoluble” extract. Pro-
tein concentrations were determined using the
BCA protein assay kit (Pierce Biotechnology).
The Meso-Scale Discovery multiplex ELISA system was used to measure
A1–38, A1– 40, and A1– 42 levels in the soluble and insoluble ex-
tracts (V-PLEX A Peptide Panel 1 (6E10) Kit; MSD).
Quantitative RT-PCR. RNA was extracted from the right hippocam-
pus using the E.Z.N.A. Total RNA kit (Omega Bio-Tek) according to the
manufacturer’s instructions. RNA was quantified using the Biospec nano
spectrophotometer. cDNA was produced using the cDNA High Capacity
kit (ThermoFisher) according to the manufacturer’s instructions. RT-
PCR was performed using the Fast TaqMan Gene Expression assay
(ThermoFisher). In each well of a 96 well plate, 0.5 l cDNA (100 ng,
based on the RNA concentrations) was diluted with 6.5 l RNase-free
water. One microliter of the appropriate gene probe was added along
with 10 l of Fast TaqMan to each well. Target amplification was per-
formed using the ViiA7 (Applied Biosystems). All genes were normalized
to 18S rRNA, and the fold change was determined using the Ct
method. Results from all APP/PS1 mice were compared with APP/PS1
mice on control diet with IgG2a treatment. Table 1 shows the genes tested
along with their PMID and TaqMan ID.
Analysis. Data are presented as mean  SEM. Statistical analysis was
performed using the JMP statistical analysis software program (SAS In-
stitute). RAWM data were analyzed by repeated-measures ANOVA. We
also performed Student’s t test on individual block data for the radial arm
water maze analysis. For other data, one-way ANOVA and Student’s t test
were performed. Statistical significance was assigned when the p value
was 0.05.
Results
Administration of a diet deficient in folate, vitamins B6 and B12
and enriched in methionine to 9-month-old WT and APP/PS1
mice for 6 months resulted in elevated plasma homocysteine lev-
els as shown in Figure 1C. In C57BL/6 mice, a level of homocys-
teine between 5 and 12 M is considered normal. Elevated levels
of homocysteine can be categorized as mild with levels between
12 and 30 M, moderate with levels between 30 and 100 M, and
severe with levels 100 M. The mice on control diet had plasma
homocysteine levels below the detection range of the clinical as-
say. Mice on our normal house chow also have levels below the
detection range showing that mice on the control diet have a
normal level of homocysteine. Plasma homocysteine levels in our
mice on the HHcy diet reached moderate to severe levels ranging
from 67 to 145 M in all cases, thus inducing hyperhomocysteine-
mia. Statistically, the only comparison showing significant differ-
ences was between the APP/PS1 mice on control diet receiving
3D6 and the APP/PS1 mice on the HHcy diet receiving the 3D6
treatment (Fig. 1C).
We performed the 2 d RAWM to identify changes in spatial
memory. Over the 2 d of testing, the WT mice on control diet
with IgG2a treatment learned the task. They started the task mak-
ing an average of three errors in the first block and ended with less
than one error in the last block (Fig. 2A). WT mice on the HHcy
diet had similar cognitive deficits as previously reported (Sud-
duth et al., 2013), with no effect of 3D6 or IgG2a (Fig. 2A). APP/
PS1 mice on control diet with IgG2a treatment did not learn the
task over the 2 d and were significantly impaired compared with
WT mice on control diet with IgG2a treatment by block 10, as
expected from APP/PS1 mice of this age (Fig. 2B). APP/PS1 mice
on control diet with 3D6 treatment began the task with an average
of 	4 errors in block 1 and were making less than one error by
the last block, indicating that they did learn the task and they were
indistinguishable from the WT mice on control diet with IgG2a
treatment. APP/PS1 mice on the HHcy diet with either IgG2a or
3D6 treatment did not learn the task, making a similar amount of
errors in the first and last block. At the end of day 2, they made
significantly more errors than the WT mice on control diet with
IgG2a treatment or the APP/PS1 mice on control diet with 3D6
treatment as shown in the block 10 data in Figure 2D. The APP/
Figure 1. Experimental setup. A, Mice were 9 months old when they began either the control or HHcy diet. After being on the
diet for 3 months, mice began a 3 month treatment of weekly intraperitoneal injections of 3D6 or IgG2a at 10 mg/kg. MRI was
performed 3 months after starting the diet but before intraperitoneal injection treatment, halfway through treatment, and
immediately before tissue collection. The 2 d radial arm water maze was also performed before tissue collection. B, Number of
animals per experimental group. C, Quantification of plasma total homocysteine levels.
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PS1/HHcy mice did not show the additive effects we have previ-
ously reported in this mixed pathology APP/PS1/HHcy mouse
(Sudduth et al., 2014); however, as can be seen from the learning
curve of the APP/PS1 mice, there was essentially a “ceiling effect,”
likely due to the older age of the mice in the current study. There-
fore, we were unable to detect any potential worsening resulting
from the HHcy component.
Total A immunohistochemistry was used to determine the
efficacy of an anti-A immunotherapy to reduce A levels in our
comorbidity model. In the frontal cortex, total A was signifi-
cantly reduced in the APP/PS1 mice on control diet with 3D6
treatment compared with APP/PS1 mice on control diet with
IgG2a treatment (Fig. 3E). Levels were slightly reduced in the
APP/PS1 mice on the HHcy diet with 3D6 treatment but did not
reach significance. In the hippocampus, total A was significantly
reduced in both the APP/PS1 mice on control and HHcy diet with
3D6 treatment compared with APP/PS1 mice on control diet
with IgG2a treatment (Fig. 3A–E). When APP/PS1 mice on HHcy
diet with control antibody were compared with APP/PS1 mice on
HHcy diet with 3D6 antibody, there was no significant difference.
Biochemical levels of A were also measured and are shown in
Figure 3F. No significant differences were found among any of
the groups, likely due to the high variation among the individual
samples.
Congo red analysis showed that amyloid levels were reduced
in the parenchyma following 3D6 treatment in APP/PS1 mice on
both the control diet and the HHcy diet when they were com-
pared with APP/PS1 mice on control diet with control antibody
(Fig. 4E). This effect was more pronounced in the hippocampus
than the frontal cortex. In contrast to the total amyloid reduc-
tions, the APP/PS1 mice on the HHcy diet showed significant
increases in CAA relative to the APP/PS1 mice on control diet.
This effect was not influenced by 3D6 administration, replicating
our previous report that HHcy leads to redistribution of amyloid
to the vasculature (Sudduth et al., 2014). The 3D6 administration
in the APP/PS1 mice on control diet caused a modest increase in
CAA relative to control antibody.
We used T2* MRI imaging to detect microhemorrhages as de-
scribed previously (Sudduth et al., 2013). At the first imaging session,
3 months into the diet but immediately before the initiation of
anti-A immunotherapy, we found modest, nonsignificant in-
creases in microhemorrhages resulting from the administration of
the HHcy-inducing diet, consistent with our previous reports (Fig.
5B). Six weeks into immunotherapy treatment, we found that there
were significant increases in microhemorrhages resulting from the
HHcy inducing diet; however, the control IgG2a and 3D6 groups
were still comparable. In contrast, 12 weeks into immunotherapy
treatment, immediately before cognitive testing and tissue harvest,
we found that microhemorrhage numbers were significantly greater
in the APP/PS1 mice on the HHcy or control diet receiving 3D6
antibody than either the APP/PS1 mice on control diet or the HHcy
diet receiving IgG2a treatment.
Prussian blue histological analysis of microhemorrhages
showed a significant increase in the number of microhemor-
rhages in each of the groups compared with APP/PS1 mice on
control diet with IgG2a treatment (Fig. 6B). The APP/PS1 mice
Figure 2. The 3D6 treatment does not improve cognition in APP/PS1 mice on the HHcy diet. Two day radial arm water maze data are shown for WT mice (A) and APP/PS1 mice (B). The mean
number of errors per trial was calculated for each block; each block is the average of three trials. *p  0.05, compared with all groups on each graph (one-way ANOVA). **p  0.01, compared with
all groups on each graph (one-way ANOVA). Block 10 data are graphed for the WT mice (C) and the APP/PS1 mice (D). C, **p  0.01, compared with WT, control, IgG2a and WT, control, and 3D6.
D, **p  0.01, compared with WT, control, IgG2a and APP/PS1, control, and 3D6.
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Figure 3. Total A is reduced by 3D6 treatment. Representative images of A staining in the hippocampus of APP/PS1, control, and IgG2a (A), APP/PS1, control, and 3D6 (B),
APP/PS1, HHcy, and IgG2a (C), and APP/PS1, HHcy, and 3D6 (D). A, The cornu ammonis (CA) 1, CA3, and dentate gyrus (DG) are labeled for orientation. Scale bar: A, 120 m.
E, Quantification of percentage positive stain in the frontal cortex and hippocampus. *p  0.05, compared with APP/PS1, control, and IgG2a. F, Biochemical quantification of soluble and
insoluble A1–38, A1– 40, and A1– 42  SEM.
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Figure 4. HHcy redistributes amyloid to the vasculature. Representative images of Congo red staining in the hippocampus of APP/PS1, control, and IgG2a (A), APP/PS1, control, and 3D6
(B), APP/PS1, HHcy, and IgG2a (C), and APP/PS1, HHcy, and 3D6 (D). A, The CA1, CA3, and DG are labeled for orientation. Scale bar: A, 200 m. Representative images of Congo red staining in the
cortex of APP/PS1, control, and IgG2a (E), APP/PS1, control, and 3D6 (F ), APP/PS1, HHcy, and IgG2a (G), and APP/PS1, HHcy, and 3D6 (H ). Scale bar: E, 50 m. Black (Figure legend continues.)
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on the HHcy diet with IgG2a treatment also had significantly
more microhemorrhages compared with the 3D6-treated APP/
PS1 mice on control diet. Also, the APP/PS1 mice on the HHcy
diet with 3D6 treatment had a significant increase in microhem-
orrhages compared with all the other groups. The majority of
microhemorrhages were located in the parietal and occipital cor-
tex with no differences in location between any of the groups.
Images of a positive Prussian microhemorrhage are shown in
Figure 6A.
One of the proposed mechanisms for anti-A immunothera-
py’s reduction of A involves activation of microglia leading to
phagocytosis of A. We performed immunohistochemistry for
CD11b, which labels both activated and resting microglia, to de-
termine whether there was an increase in total microglia. In both
the frontal cortex and the hippocampus, CD11b was slightly in-
creased in the APP/PS1 mice on control diet with 3D6 treatment
compared with the APP/PS1 mice on control diet with IgG2a
treatment (Fig. 7E), but this was not significant. CD11b staining
was significantly reduced in the frontal cortex in the APP/PS1
mice on the HHcy diet with 3D6 treatment compared with the
APP/PS1 mice on control diet with 3D6 treatment. In the hip-
pocampus, the APP/PS1 mice on the HHcy diet with IgG2a or
3D6 treatment had significantly reduced levels of CD11b staining
compared with the APP/PS1 mice on control diet with 3D6 treat-
ment (Fig. 7A–E). The amount of CD11b staining was also
slightly reduced in the APP/PS1 mice on the HHcy diet with
IgG2a or 3D6 treatment compared with APP/PS1 mice on con-
trol diet with IgG2a treatment.
Using several genetic markers specific to a proinflamma-
tory, wound healing/repair or immune complex-mediated
macrophage phenotype (Mantovani et al., 2005; Walker and
Lue, 2015), we characterized the neuroinflammatory re-
sponse. The data in Figure 8 are shown as a fold change from
the APP/PS1 mice on control diet with IgG2a treatment. The
APP/PS1 mice on control diet with 3D6 treatment showed a
significant increase in several proinflammatory markers (spe-
cifically IL1 and TNF) and increases in several immune
complex-mediated genes (FcR1 and FcR3) (Fig. 8 A, C). The
APP/PS1 mice on the HHcy diet with IgG2a treatment showed
elevations in several wound healing/repair genes (ARG1) (Fig.
8B). The APP/PS1 mice on the HHcy diet with 3D6 treatment
only showed significant changes in some immune complex-
mediated genes (FcR1 and FcR3) (Fig. 8C). There were also
several significant increases in the expression of the MMP2
and MMP9 system markers as shown in Figure 8D. The APP/
PS1 mice on control diet with 3D6 treatment showed a signif-
icant increase in MMP2, MMP3, and MMP9. The APP/PS1
mice on the HHcy diet showed an increase in MMP9 expres-
sion as well.
Discussion
While AD is the most common form of dementia, VCID is the
second most common, and it is estimated that 40% of AD pa-
tients also have some form of VCID (Bowler et al., 1998; Zekry et
al., 2002; Langa et al., 2004; Van Iterson et al., 2015). One prom-
4
(Figure legend continued.) arrows indicate Congo staining around a vessel (CAA). I, Quantifi-
cation of percentage positive stain in the frontal cortex and hippocampus. *p 0.05, compared
with APP/PS1, control, and IgG2a. **p  0.01, compared with APP/PS1, control, and IgG2a.
Figure 5. The 3D6 increases MRI detected microhemorrhages. A, Representative T2* images of 3D6-treated mice. Arrows indicate a microhemorrhage. B, Quantification of the number of
microhemorrhages per section over the 3 imaging sessions. *p  0.05, compared with APP/PS1, control, and IgG2a. **p  0.01, compared with APP/PS1, control, and IgG2a.
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ising therapeutic for AD is anti-A immunotherapy, which uses
antibodies against A to clear it from the brain. In mice, anti-A
immunotherapy significantly reduced A levels and improved
cognitive outcomes (Schenk et al., 1999; Morgan et al., 2000;
Wilcock et al., 2004a, b); however, in clinical trials, anti-A im-
munotherapy failed to reach primary cognitive outcomes in sev-
eral different clinical trials (Salloway et al., 2014; Siemers et al.,
2016). In addition, anti-A immunotherapy has been associated
with adverse cerebrovascular events. In mice, these manifested as
microhemorrhages (Pfeifer et al., 2002; Wilcock et al., 2004b;
Racke et al., 2005), whereas in clinical trials, it presented as vaso-
genic edema, detected using MRI imaging techniques. These ad-
verse events were termed amyloid related imaging abnormalities
(ARIA). Under this term, they were called ARIA-H (hemor-
rhagic) and ARIA-E (vasogenic edema) (Sperling et al., 2011).
We hypothesized that one potential reason the anti-A immuno-
therapy clinical trials were unsuccessful, both cognitively and
with respect to the ARIA, was due to this high percentage of VCID
comorbidity in the AD population. We used our unique model of
VCID-amyloid comorbidity to test this hypothesis.
We placed 9-month-old WT and APP/PS1 mice on either a
control diet or a diet that induces HHcy. Our laboratory has
previously shown that a diet deficient in vitamins B6 and B12 and
folate and enriched in methionine induces HHcy (Sudduth et al.,
2014), which is a risk factor for VCID and cardiovascular disease
(Bostom et al., 1999; Eikelboom et al., 1999). After being placed
on the diet for 3 months, the mice then received intraperitoneal
injections of either IgG2a or 3D6 for another 3 months. While we
found that treatment of our comorbidity model with 3D6 re-
sulted in decreased total A levels, there was no cognitive benefit
of the anti-A immunotherapy in our AD/VCID mice. Further,
microhemorrhages were increased by 3D6 in the APP/PS1 on
control diet but further increased in an additive fashion when
3D6 was administered to the APP/PS1/HHcy mice.
Total A deposition, which is mostly diffuse deposition, was
reduced in the 3D6-treated animals, both APP/PS1 and APP/
PS1/HHcy compared with APP/PS1 controls. Total A deposi-
tion in the APP/PS1 mice on HHcy diet with 3D6 were not
significantly different compared with APP/PS1 mice on HHcy
diet with IgG2a, although they did show trends for reduction. We
found that amyloid distribution was altered when we examined
Congo red staining. When we looked at parenchymal versus vas-
cular Congophilic amyloid deposition using our previously de-
scribed method (Wilcock et al., 2006), we saw that the HHcy diet
resulted in an apparent redistribution of the amyloid to the vas-
culature, as CAA, replicating our previous finding (Sudduth et
al., 2014). We did not find that 3D6 altered this outcome. Inter-
estingly, despite the comparable levels of CAA between the
3D6-treated and control antibody-treated APP/PS1/HHcy mice,
microhemorrhages were significantly increased in the 3D6-
treated mice, indicating that the microhemorrhages do not occur
Figure 6. The 3D6 and HHcy increase Prussain blue detected microhemorrhages. A, Representative images of Prussian blue-positive microhemorrhages in the frontal cortex. Scale bar,
120 m. B, Quantification of the mean number of microhemorrhages per section. **p  0.01, compared with APP/PS1, control, and IgG2a. Black bars represent significant differences
between connecting groups.
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Figure 7. CD11b staining is decreased in the HHcy groups. Representative images of CD11b staining in the hippocampus of APP/PS1, control, and IgG2a (A), APP/PS1, control, and 3D6
(B), APP/PS1, HHcy, and IgG2a (C), and APP/PS1, HHcy, and 3D6 (D). A, The CA1, CA3, and DG are labeled for orientation. Scale bar: A, 120 m. Higher-magnification (Figure legend continues.)
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simply due to the presence of CAA, but that the anti-A antibody
causes a local reaction at the vessel, resulting in leakage.
We have previously shown that MMP activation, in particular
MMP9, is associated with tight junction breakdown and microhem-
orrhages, both in response to immunotherapy (Wilcock et al., 2011)
and in the HHcy model (Sudduth et al., 2013, 2014). MMP9 has
been implicated in cerebrovascular injury, including hemorrhagic
transformation after stroke and microhemorrhage occurrence in
CAA (Lee et al., 2003; Jickling et al., 2014). In our study, both 3D6
and HHcy significantly increased gene expression of MMP9, similar
to previous studies. MMP3, an activator of MMP9, was also in-
creased in the 3D6-treated control APP/PS1 mice.
It is unclear what mechanism is responsible for the increased
MMP9 and MMP3 in the current study. MMP9 and MMP3 can
be activated by proinflammatory cytokines, such as IL1 and
TNF (Galis et al., 1994; Vecil et al., 2000). As a result of this
literature and our previous data (Sudduth et al., 2013; Sudduth et
al., 2014), we explored neuroinflammation in the current study.
Our findings were intriguing and suggest that the immunother-
apy did not result in an overt inflammatory response by the
microglia. TNF and IL1 were only significantly increased in
the 3D6-treated control APP/PS1 mice and not in either of the
HHcy-treated groups. Indeed, both the HHcy-treated groups had
a slight reduction in CD11b staining and did not show any
changes in the majority of markers for any of the neuroinflam-
matory states. In our previous study, we showed that the APP/
PS1 mice on the HHcy diet had a neuroinflammatory shift from
wound healing and repair to a proinflammatory state (Sudduth et
al., 2014). Because of the older age of the mice in this study (15
months rather than 12 months), and the addition of a treatment
arm, the mice could have progressed past this neuroinflamma-
tory shift. Unfortunately, we are only able to assess the changes
postmortem, and thus cannot know what changes preceded those
reported here. Based on our data, we hypothesize that either there
is a decrease in the numbers of microglial cells or the microglia
could be senescent. The constant activation from high A levels,
long-term HHcy, and weekly administration of antibodies could
force the microglia into senescence, resulting in the decreased
CD11b staining and lack of immune activation. It is also possible
that the decreased CD11b staining, which also labels other my-
eloid cells like monocytes, could also result from HHcy suppres-
sion of infiltration of peripheral cells, although this seems
4
(Figure legend continued.) images of CD11b staining in the dentate gyrus of APP/PS1, control,
and IgG2a (E), APP/PS1, control, and 3D6 (F), APP/PS1, HHcy, and IgG2a (G), and APP/PS1,
HHcy, and 3D6 (H). Scale bar: E, 50 m. I, Quantification of percentage positive stain in the
frontal cortex and hippocampus.
Figure 8. HHcy reduced inflammatory markers and increased the MMP system markers in both the IgG2a and 3D6 groups. Data are shown as a fold change from APP/PS1, control, and IgG2a.
Relative gene expression for proinflammatory markers (A), would healing/repair markers (B), immune complex-mediated markers (C), and MMP2 and MMP9 system markers (D). *p  0.05,
compared with APP/PS1, control, and IgG2a. **p  0.01, compared with APP/PS1, control, and IgG2a.
Weekman et al. • Anti-A Immunotherapy in a Comorbidity Model J. Neurosci., September 21, 2016 • 36(38):9896 –9907 • 9905
unlikely because the HHcy diet results in a microhemorrhage
induction. Therefore, while MMP9 may be responsible for the
tight junction breakdown leading to microhemorrhages, proin-
flammatory cytokines do not seem to be the stimulating factor in
the current study.
Previous anti-A immunotherapy studies have shown that
the use of anti-A antibodies significantly improves cognitive
outcomes in mice (Schenk et al., 1999; Morgan et al., 2000; Wil-
cock et al., 2004a, b). While we saw that 3D6 treatment signifi-
cantly reduced the number of errors APP/PS1 mice on control
diet made making then indistinguishable from the WT controls,
the presence of HHcy impeded those benefits. The APP/PS1 mice
on the HHcy diet with 3D6 treatment did not benefit cognitively
from the anti-A immunotherapy. Indeed, they were not signif-
icantly different from the APP/PS1 mice on the HHcy diet with
IgG2a treatment by the end of the second day. This lack of
cognitive benefits could be due to the increase in the number of
microhemorrhages seen in the 3D6-treated HHcy mice com-
pared with the 3D6 or HHcy controls, or the increased levels of
CAA. We cannot rule out that there may have been a benefit to
the APP/PS1/HHcy that was undetected in our selected behav-
ioral task due to wild-type HHcy mice also reaching a ceiling
effect. Future studies will try to develop more sensitive behavioral
tasks that may discriminate these effects. Despite the A reduc-
tions in the APP/PS1/HHcy mice, the increase in vascular damage
and leakage appears to negate any cognitive benefits of clearing
the A. This suggests that anti-A immunotherapy in patients
with VCID comorbid with AD may be ineffective with respect to
functional outcomes. Prescreening subjects for cerebrovascular
pathologies before enrollment in anti-A immunotherapy clini-
cal trials may reduce the adverse cerebrovascular events seen dur-
ing treatment, and this could result in significantly improved
cognitive outcomes. Although anti-A immunotherapy trials are
moving toward treatment of prodromal AD, VCID still remains a
concern because the immunotherapy could hasten any vascular
dysfunction that is present but asymptomatic.
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